数千万B+轮！医疗大模型企业一年完成三轮融资

Core Viewpoint - Hangzhou Quanzhen Medical Technology Co., Ltd. has completed a B+ round financing of several tens of millions, led by PwC Capital, with the funds aimed at deepening the research and development of its core product, the "Quanzhen Medical Large Model and Clinical Application," and expanding into overseas markets [1][13]. Company Overview - Quanzhen Medical, founded in Hangzhou, is one of the earliest innovative companies in China focusing on the post-training and clinical application of medical large models, with a mission to "enhance doctors' capabilities through AI" [2]. - The founder, Dr. Xue Chong, has a dual background as a clinical doctor and AI researcher, which provides a deep understanding of AI's value in healthcare, emphasizing that AI should assist rather than replace doctors [4]. Product and Technology - The flagship product, "Quanzhen Tong (Trizen AI)," is the first intelligent medical record and clinical assistance system for doctors in China, featuring automatic medical record generation, clinical decision support, and patient service [6]. - The system significantly improves medical record writing efficiency by over 65% and supports various types of medical documents, with accuracy and logical language superior to similar products in the industry [6][10]. - Quanzhen Medical is expanding its product from a single medical record tool to a comprehensive "AI Doctor Assistant" platform, covering the entire process from pre-diagnosis to follow-up [6]. Technical System - Since 2023, Quanzhen Medical has established a complete "foundation-model-application" technical system, focusing on post-training methods tailored for medical scenarios [7]. - The system utilizes localized large model deployment, compressing general models into medical-specific models with parameters ranging from 1 billion to 10 billion, enhancing response speed and reducing inference costs [10]. - The company has developed a multi-dimensional training system, including supervised fine-tuning, reinforcement learning, and generative adversarial networks, significantly reducing common issues like "hallucinations" and misjudgments in medical large models [10][11]. Industry Trends - The global medical AI sector continues to heat up, with companies like Abridge and Open Evidence seeing rising valuations, driven by the need for valuable medical large models to be deeply integrated into real "diagnostic processes" [12]. - Quanzhen Medical exemplifies this trend by focusing on the practical application of AI in clinical settings, aiming to provide world-class intelligent solutions [12].